Director’s Major Stock Sale Shakes Up Mineralys Therapeutics!

New insider activity at Mineralys Therapeutics, Inc. ( (MLYS) ) has taken place on November 21, 2025.

Director Brian Taylor Slingsby has made a significant move by selling 1,000,000 shares of Mineralys Therapeutics, Inc. stock, amounting to a total transaction value of $43,350,000.

Recent Updates on MLYS stock

Mineralys Therapeutics, Inc. experienced a significant stock price decline of 13.9% to $38.15, despite positive developments in its clinical and financial outlook. The company recently held an earnings call that highlighted successful clinical trial outcomes for its drug lorundrostat, which demonstrated a meaningful reduction in systolic blood pressure across diverse patient populations. Financially, Mineralys reported a strong position with $593.6 million in cash and investments, sufficient to fund operations into 2028. The company’s net loss decreased due to reduced research and development expenses. H.C. Wainwright raised the price target for Mineralys, driven by enthusiasm for the upcoming NDA submission for lorundrostat. However, challenges such as data imputation concerns and increased general and administrative expenses were noted. Overall, the company’s strategic planning and financial stability suggest a promising future, despite the recent stock price drop.

Spark’s Take on MLYS Stock

According to Spark, TipRanks’ AI Analyst, MLYS is a Neutral.

Mineralys Therapeutics shows promise with positive clinical trial results and a strong cash position, but faces challenges with continuous losses and negative cash flows. Technical analysis suggests short-term momentum, while valuation remains a concern due to lack of revenue. The earnings call highlighted upcoming milestones that could enhance future prospects.

To see Spark’s full report on MLYS stock, click here.

More about Mineralys Therapeutics, Inc.

YTD Price Performance: 241.80%

Average Trading Volume: 1,896,706

Technical Sentiment Signal: Buy

Current Market Cap: $3.33B